University Hospitals Birmingham NHS Foundation Trust | FOI 0630 Multiple Sclerosis Treatments 2019/20

Freedom of Information Request: 0630 2019/20

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1^st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust some responses have been provided by hospital sites Queen Elizabeth Hospital (QE) and Heartlands, Good Hope and Solihull Hospitals (HGS).

Could you please provide us with the numbers of patients in relation to the questions mentioned below, for a period of last 12 months:

In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?

722

Of these MS patients, how many have been diagnosed with relapsing (RRMS), primary progressive (PPMS) or secondary progressive (SPMS) MS;

The trust does not hold this information in a way it allows us to retrieve accurate data.

If you do not code your MS patients in this way, do you have plans to do this?

RRMS

PPMS

SPMS

Not known

How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:

Aubagio (teriflunomide)

Avonex (interferon beta-1a)

Betaferon (interferon beta-1b)

Brabio (glatiramer acetate)

Copaxone (glatiramer acetate)

Extavia (beta interferon-1b)

Gilenya (fingolimod)

Lemtrada (alemtuzumab)

Mavenclad (cladribine)

Mayzent (siponimod)

Ocrevus (ocrelizumab)

Plegridy (peginterferon beta-1a)

Rebif (beta interferon-1a)

Tecfidera (dimethyl fumarate)

Tysabri (natalizumab)

Vumerity (diroximel fumarate)

Zinbryta (daclizumab)

Ampyra (fampyra)

Ozanimod

Queen Elizabeth Hospital Birmingham (QE):

Drug	Number_of_patients
Ampyra (fampyra)	0
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	0
Betaferon (interferon beta-1b)	0
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	0
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	22
Lemtrada (alemtuzumab)	1
Mavenclad (cladribine)	0
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	0
Ozanimod	0
Plegridy (peginterferon beta-1a)	0
Rebif (beta interferon-1a)	0
Tecfidera (dimethyl fumarate)	2
Tysabri (natalizumab)	4
Vumerity (diroximel fumarate)	0
Zinbryta (daclizumab)	0

Heartlands, Good Hope and Solihull (HGS):

The HGS systems do not allow us to retrieve this information accurately.

Of the patients who are receiving Ocrevus (Ocrelizumab) , how many are primary progressive (PPMS)? If unknown, please state unknown

Unknown.

How many patients have been treated with these drugs in the past 6 months, regardless of diagnosis.

Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Brabio (glatiramer acetate)